Introduction {#s1}
============

The retinal pigmented epithelium (RPE) is a monolayer of polarized and highly specialized pigmented cells that are located between the outer segments of the photoreceptors and the choroid layer in the eye. This strategic location demands multiple functions of the RPE during the development and homeostasis of the adjacent tissues, the neuroretina and choroid [@pgen.1004360-Strauss1]. The RPE is a major component of the blood retinal barrier and it therefore determines the microenvironment of the photoreceptors. RPE cells are also responsible for photoreceptor outer segment phagocytosis and are directly involved in retinoid metabolism [@pgen.1004360-Strauss1]. An important and evolutionarily conserved role of the RPE is the absorption of stray light to increase visual acuity and reduce oxidative damage. This latter activity requires functional melanosomes, which contain enzymes that catalyze the production of melanin (e.g. tyrosinase, TYR; tyrosinase-related protein, TYRP1; and dopachrome tautomerase, DCT) [@pgen.1004360-delMarmol1], [@pgen.1004360-Hearing1]. Melanosomes accumulate in the RPE during cellular differentiation [@pgen.1004360-Burke1]. Defects in any of these complex functions of the RPE may lead to photoreceptor degradation and, eventually, blindness. Considering the importance of the RPE for ocular physiology and the recent breakthroughs in technologies involving gene transfer and cellular based therapies for treating RPE malfunctions, there is a need to understand the molecular and cellular mechanisms that regulate the acquisition of the various specialized functions of this important tissue.

Most pigmented cells in the body originate from the neural crest. In contrast, the RPE is derived from the neural epithelium of the optic vesicles (OV), which are lateral protrusions of the ventral forebrain. The OV undergo patterning and morphogenesis to give rise to the bilayer optic cup (OC) with an inner layer of retinal progenitor cells and an outer layer populated by the progenitors of the pigmented epithelium. The distal regions of the OC differentiate into the epithelial layers of the ciliary body and iris [@pgen.1004360-Davis1]. The partitioning of the optic neuroepithelium into neuronal and pigmented precursors depends on the activity of extrinsic and intrinsic cues such as transforming growth factor-betab (TGFb) and WNT ligands, which promote RPE development, and fibroblast growth factors (FGFs), which play a role in inducing neuronal fates [@pgen.1004360-Fuhrmann1]--[@pgen.1004360-Zhao1].

Extrinsic cues trigger the expression and activity of intrinsic factors that execute the differentiation program. A pivotal intrinsic mediator of the RPE fate is microphthalmia-associated transcription factor (MITF), a member of the basic-helix-loop-helix leucine zipper family known to be essential for melanin-bearing pigment cells across species and tissue types [@pgen.1004360-Bharti1]. MITF binds the DNA as a homodimer to stimulate the expression of its target genes [@pgen.1004360-Aksan1], [@pgen.1004360-Lowings1]. MITF is also able to form DNA-binding heterodimers with the related factors TFE3, TFEB and TFEC [@pgen.1004360-Hemesath1]. The *Mitf* gene encodes a family of at least 10 distinct isoforms generated from a common gene by alternative promoter/exon usage [@pgen.1004360-Bharti2], [@pgen.1004360-Li1]. Of these, *M*-*Mitf* is expressed in the neural crest derived pigment cells [@pgen.1004360-Hodgkinson1], [@pgen.1004360-Levy1], and *A-Mitf*, *H*-*Mitf* and *D*-*Mitf* are highly expressed in the developing RPE where they are equally distributed [@pgen.1004360-Bharti2], [@pgen.1004360-Takeda1]. The mRNAs of *Mitf* isoforms *M*, *A*, *H* and *D* contain different non-coding and coding 5′ sequences and the corresponding proteins thus differ in their N-terminal sequences [@pgen.1004360-Bharti2], [@pgen.1004360-Takeda1]. However, each of these protein isoforms can regulate the expression of the melanogenic genes [@pgen.1004360-Takeda1]--[@pgen.1004360-Yajima1].

In melanocytes, PAX3, SOX10, CREB and the canonical WNT3A signaling pathway regulate the expression of the *M-Mitf* isoform [@pgen.1004360-Bondurand1]--[@pgen.1004360-Watanabe1]. In contrast, in the RPE, where *Pax3* is not expressed, data suggest that PAX6 plays a role in regulating the onset of *Mitf* expression [@pgen.1004360-Baumer1]. *Pax6*, the homolog of the *eyeless* (*ey)* gene in *Drosophila*, is pivotal for development of eye cell types derived from the neuroepithelium or from the surface ectoderm (reviewed in [@pgen.1004360-Shaham1] and [@pgen.1004360-Kozmik1]). Moreover, ectopic expression of *Pax6* in frog embryos leads to formation of a differentiated eye, thus demonstrating a role for PAX6 in the different ocular lineages including the RPE [@pgen.1004360-Chow1]. The evolutionarily conserved roles of PAX6 and its upstream regulatory functions suggest that in ocular tissue types *Pax6* is a kernel gene, a term referring to the hierarchically upper-most gene in a gene regulatory network [@pgen.1004360-Davidson1].

*Pax6* is abundantly expressed during patterning of the OV and during specification and differentiation of the RPE. Several studies indicate that PAX6 is important in the specification of the RPE. Recently it was shown that a reduction in *Pax6* gene dosage leads to development of neuroretina instead of RPE in embryos that are heterozygous for a mutation in *Mitf*, while embryos with such a mutation and normal *Pax6* levels do not exhibit any detectable phenotype [@pgen.1004360-Bharti3]. Furthermore, at the OV stage, the redundant activities of PAX6 and PAX2 are required for the early patterning of the OV by regulating *Mitf* expression [@pgen.1004360-Baumer1]. Later in development, PAX6, but not PAX2, is detected in the RPE [@pgen.1004360-Baumer1]. These findings establish a role for PAX6 during the RPE specification stage and imply that PAX6 is also important during the differentiation of the RPE, although its role at this stage is still unknown.

The goal of this study was to examine the roles of *Pax6* during RPE differentiation, after the specification of the RPE is established. We show that during the onset of RPE differentiation PAX6 regulates the expression of *Mitf* and at the same time PAX6 functions together with MITF to activate the expression of downstream targets that execute melanogenesis in the RPE. Our findings reveal the molecular mechanism through which a single transcription factor, which is expressed in multiple ocular and non-ocular cell types, controls a highly specialized differentiation program of the neuroepithelium-derived pigmented cells of the eye.

Results {#s2}
=======

PAX6 is required for the pigmentation program of the RPE {#s2a}
--------------------------------------------------------

Once the optic cup has formed (around E10.5), RPE progenitors begin to accumulate melanin [@pgen.1004360-Drager1], [@pgen.1004360-Strongin1]. During the initiation of the pigmentation program, the expression of PAX6 is detected throughout the RPE layer (E10- E12.5, [Figure 1A](#pgen-1004360-g001){ref-type="fig"}). In later stages, the expression of PAX6 is gradually reduced, first in the central and subsequently in the peripheral optic cup ([Figure S1A](#pgen.1004360.s001){ref-type="supplementary-material"}-D). PAX6 is eventually maintained in the pigmented cells of the ciliary body (CB) and iris. To study the role of PAX6 in the RPE after its specification and during the first steps of its differentiation, we generated *Pax6^loxP/loxP^;DctCre* mice in which *loxP* sites are located in exon 4 upstream of the initiator ATG and in intron 6 [@pgen.1004360-Davis1], [@pgen.1004360-AsheryPadan1], [@pgen.1004360-Zhao2]. The *Dct* promoter is active in the dorsal side of the OV at E9.5 and by E12.5 its activity is detected in the outer layer of the OC in RPE progenitors [@pgen.1004360-Davis1], [@pgen.1004360-Zhao2].

![PAX6 expression is essential for proper pigment accumulation in the RPE but dispensable for RPE polygonal and single layer morphology.\
(A-N) RPE of (A-E,K,L) *Pax6^loxP/loxP^* and (F-J,M,N) *Pax6^loxP/loxP^;DctCre* mice analyzed for (A,F) PAX6 expression, (B,C,E,G,H,J,K,M) pigment accumulation and (D,L,I,N,O) morphology and specification. (A,F) Paraffin sections of E12.5 eyes were stained for PAX6 N-terminus and (B,G) viewed by differential interference contrast imaging. Scale bar is 100 µm. (C,H) Whole eye images of E19.5 mice. (D,E,I,J) Transmission electron microscope images of E15.5 eyes. Dashed lines mark the apical and basal membranes of the cells; arrowheads indicate melanosomes. Scale bar is 2 µm. (K-N) RPE flat-mount views of E19.5 eyes (K,M) using bright field or (L,N) stained for actin. Scale bar is 100 µm. (O) Relative transcript levels of *connexin-43* (a gap junction marker), *P-cadherin* (an adherens junction marker) and *ZO-1* (a tight junction marker) from control and *Pax6*-deficient E15.5 RPE fractions determined using QRT-PCR (n = 6). Abbreviations: CB, ciliary body; CC, choriocapilaris; N, nucleus; PR, photoreceptors.](pgen.1004360.g001){#pgen-1004360-g001}

Corresponding with *DctCre* activity and the location of the *loxP* sequences, the PAX6 paired domain was lost from the optic cup as evident from labeling with an antibody that specifically identifies the N-terminus of PAX6 (E12.5, [Figure 1F](#pgen-1004360-g001){ref-type="fig"} and [Figure S1A](#pgen.1004360.s001){ref-type="supplementary-material"}-H, red). Nevertheless, a C-terminal fragment of PAX6 was detected in the *Pax6^loxP/loxP^;DctCre* mice when using polyclonal antibodies that detect this region of the protein ([Figure S1](#pgen.1004360.s001){ref-type="supplementary-material"}, green). The expression of this variant lacking the paired domain (PD) of PAX6 (PAX6ΔPD) was transient and reliably mimicked that of the full-length PAX6 during development as the PAX6ΔPD gradually disappeared in a central to peripheral pattern and was eventually lost from the RPE at around birth ([Figure S1](#pgen.1004360.s001){ref-type="supplementary-material"}, green).

We further characterized the expression of *Pax6ΔPD* transcripts in the mutant RPE: a first *Pax6ΔPD* transcript variant was generated from the P4 promoter and was also detected in control RPE at E16 by RT-PCR and *in situ* hybridization using a specific probe ([Figure S2A](#pgen.1004360.s002){ref-type="supplementary-material"},C,E). A second *Pax6ΔPD* variant was generated due to aberrant splicing between exon 3 and 7 ([Figure S2B](#pgen.1004360.s002){ref-type="supplementary-material"},D). Nonetheless, we did not detect over-expression of exons 7-8, located upstream of the homeodomain (HD), in the mutated RPE by quantitative real-time PCR (QRT-PCR, [Figure S2F](#pgen.1004360.s002){ref-type="supplementary-material"}). Thus, the *Pax6^loxP/loxP^;DctCre* mice constitute a genetic model for determining the role of the full-length PAX6 protein, while not excluding activities mediated by PAX6ΔPD.

The phenotype of the *Pax6^loxP/loxP^;DctCre* eyes was evident during embryogenesis as the iris and CB progenitors, which are evident at E19.5 ([Figure 1C](#pgen-1004360-g001){ref-type="fig"}), did not develop in the *Pax6^loxP/loxP^;DctCre* OC ([Figure 1H](#pgen-1004360-g001){ref-type="fig"}) in agreement with a previous report [@pgen.1004360-Davis1]. In addition, reduced pigmentation in the RPE was noted from early stages of RPE differentiation (E12.5, [Figure 1B,G](#pgen-1004360-g001){ref-type="fig"}) and was evident when viewing the whole eye of *Pax6^loxP/loxP^;DctCre* as compared to control litter mates (E19.5, [Figure 1C,H](#pgen-1004360-g001){ref-type="fig"}) or in flat mount (E19.5, [Figure 1K,M](#pgen-1004360-g001){ref-type="fig"}).

Although pigmentation was reduced, the fate of the RPE was maintained in the *Pax6*-mutant RPE based on the expression of the transcription factors *Otx2* and *Sox9* ([Figure S3](#pgen.1004360.s003){ref-type="supplementary-material"}). Consistent with maintenance of RPE fate, transmission electron microscope (TEM) analysis conducted on E15.5 control and *Pax6^loxP/loxP^;DctCre* eyes ([Figure 1D,E,I,J](#pgen-1004360-g001){ref-type="fig"}) demonstrated that the typical RPE morphology of a single layer was preserved despite reduction in pigmentation. The adjacent structures of the choriocapillaris and neuroretina maintained normal morphology despite *Pax6* loss in the RPE ([Figure 1D,I](#pgen-1004360-g001){ref-type="fig"}). We next examined actin distribution by phalloidin staining in flat mounts of the RPE and observed that the typical polygonal morphology of the RPE was maintained ([Figure 1L,N](#pgen-1004360-g001){ref-type="fig"}). Moreover, using QRT-PCR analysis we did not detect significant differences between control and *Pax6*-deficient RPE in the levels of mRNAs encoding the intercellular junction proteins ZO-1, Connexin-43 and P-cadherin (E15.5, [Figure 1O](#pgen-1004360-g001){ref-type="fig"}). These findings reveal a role for PAX6 in execution of the pigmentation program, although its absence does not alter the fate and morphology of the RPE at the OC stage.

PAX6 is required for the expression of key melanogenic genes {#s2b}
------------------------------------------------------------

To determine the global change in gene expression following *Pax6* loss in the OC we determined the transcript profile in control and *Pax6^loxP/loxP^;DctCre* E15.5 RPE using Affymetrix GeneChip Mouse Gene 1.0 ST arrays. Of the 28,853 genes represented on the microarray, levels of 100 transcripts were significantly altered in mutant RPE, compared to the wild-type (fold change greater than 1.5, *p*\<0.05, [Table S1](#pgen.1004360.s008){ref-type="supplementary-material"}). The expression of 73 of these genes was reduced in the *Pax6*-deficient RPE. In agreement with the observed phenotype, analysis of enrichment in GO categories revealed significant representation of melanogenic genes (*p*\<0.05; using the ToppGene Suite algorithm; [@pgen.1004360-Chen1]) as summarized in [Table 1](#pgen-1004360-t001){ref-type="table"}. The identified pigmentation genes encode key enzymes of melanogenesis (*Tyr* and *Tyrp1*), as well as factors involved in melanosome biogenesis (*Si*, *Mlana*, and *Gpr143*) or melanosome transport (*RAB27a*) and factors implicated in melanosome biogenesis (*Gpnmb*, *Slc45a2*, *Slc24a5* and *Slc3a2*). Corresponding to the phenotype observed, the transcriptome analysis indicates an arrest in the melanogenesis program following *Pax6* loss.

10.1371/journal.pgen.1004360.t001

###### Melanogenic genes down-regulated in the *Pax6*-deficient RPE.

![](pgen.1004360.t001){#pgen-1004360-t001-1}

  Gene symbol                                            Gene name                                            Fold change   *p* value                       References
  ------------- -------------------------------------------------------------------------------------------- ------------- ----------- ----------------------------------------------------
  *Gpnmb*                                     Glycoprotein (transmembrane) nmb                                   −5.73       0.00020     [@pgen.1004360-Loftus1], [@pgen.1004360-Hoashi1]
  *Mlana*                                                 Melan-A                                                −4.17       0.00018                   [@pgen.1004360-Du1]
  *Gpr143*                                     G protein-coupled receptor 143                                    −2.83       0.00267    [@pgen.1004360-Cortese1], [@pgen.1004360-Incerti1]
  *Tyrp1*                                       Tyrosinase-related protein 1                                     −1.91       0.00297                [@pgen.1004360-Yasumoto1]
  *Slc45a2*                                  Solute carrier family 45, member 2                                  −1.90       0.00630       [@pgen.1004360-Costin1], [@pgen.1004360-Du2]
  *Rab27a*                                       Member RAS oncogene family                                      −1.81       0.00530                   [@pgen.1004360-Wu1]
  *Slc24a5*                                  Solute carrier family 24, member 5                                  −1.68       0.03025                  [@pgen.1004360-Vogel1]
  *Slc3a2*       Solute carrier family 3 (activators of dibasic and neutral amino acid transport), member 2      −1.66       0.00025                 [@pgen.1004360-Dooley1]
  *Si*                                                     Silver                                                −1.60       0.00721       [@pgen.1004360-Du1], [@pgen.1004360-Baxter2]
  *Tyr*                                                  Tyrosinase                                              −1.58       0.04166                [@pgen.1004360-Yasumoto1]

To validate the microarray results, six melanogenic genes were analyzed by QRT-PCR ([Figure 2A](#pgen-1004360-g002){ref-type="fig"}). In agreement with the microarray results, transcript levels of *Tyr*, *Tyrp1*, *Si* and *Mlana* were significantly reduced in the mutant RPE as compared with control, whereas the level of the mRNA encoding the enzyme DCT, which is involved in melanin synthesis, was slightly reduced, and the level of *Myo7a* mRNA, which encodes a protein involved in cellular transport of melanosomes in the RPE [@pgen.1004360-Gibbs1], was similar to wild-type. The reductions of *Si* transcript ([Figure 2B,E](#pgen-1004360-g002){ref-type="fig"}) and of TYR and TYRP1 proteins ([Figure 2C,D,F,G](#pgen-1004360-g002){ref-type="fig"}) were validated by *in situ* hybridization and antibody labeling, respectively. These findings support a role for PAX6 in the proper expression of key melanogenic genes in the RPE.

![PAX6 is required for the expression of several melanogenesis genes.\
(A) Relative levels of *Tyr*, *Tyrp1*, *Si*, *Mlana*, *Dct* and *Myo7a* transcripts in RPE of control *Pax6^loxP/loxP^* and mutant *Pax6^loxP/loxP^;DctCre* E15.5 mice determined using QRT-PCR. \**p*\<0.05, \*\**p*\<0.005, \*\*\**p*\<0.0005, (n = 5). (B-G) Control and mutant RPE (B,E) cryo-sections showing the distal OC subjected to *in situ* hybridization for *Si* and (C,D,F,G) paraffin sections labeled with antibodies against TYR and TYRP1. Scale bar is 50 µm in B and E and 25 µm in C,D,F,G.](pgen.1004360.g002){#pgen-1004360-g002}

PAX6 is required for the expression of *D-Mitf* in the developing RPE {#s2c}
---------------------------------------------------------------------

The transcription factor *Mitf* is considered the master regulator of all melanin-bearing pigment cells and several melanogenic genes are direct targets of MITF [@pgen.1004360-Cheli1], [@pgen.1004360-Steingrimsson1]. Out of the 10 melanogenic genes found to be down-regulated following *Pax6* loss, seven are known direct targets of MITF: *Tyr* and *Tyrp1* [@pgen.1004360-Yasumoto1], *Si* and *Mlana* [@pgen.1004360-Du1], *Gpnmb* [@pgen.1004360-Loftus1], *Rab27a* [@pgen.1004360-Chiaverini1] and *Gpr143* [@pgen.1004360-Vetrini1]. *Mitf* has previously been found to be regulated by PAX6 and PAX2 at the OV stage [@pgen.1004360-Baumer1]. We therefore wanted to investigate whether *Mitf* expression is dependent on PAX6 after RPE specification, when PAX2 is not expressed in the pigmented epithelium [@pgen.1004360-Baumer1].

The *Mitf* gene encodes a family of isoforms generated from a common gene. The isoforms that are predominantly expressed in the RPE are *A*, *H* and *D* [@pgen.1004360-Bharti2] ([Figure S4A](#pgen.1004360.s004){ref-type="supplementary-material"},B). The average response of all the *Mitf* probes in the GeneChip array revealed a reduction in the transcript levels by 1.37 fold (*p* = 0.069) in *Pax6*-deficient RPE compared to the wild-type. By indirect immunofluorescence (IIF) analysis we indeed detected reduced levels of MITF protein in the RPE of *Pax6^loxP/loxP^;DctCre* embryos as compared with control *Pax6^loxP/loxP^* embryos at E12.5 and at E15.5 ([Figure 3A-D](#pgen-1004360-g003){ref-type="fig"}). We next determined the expression levels of the specific *Mitf* isoforms by QRT-PCR of RNA extracted from control and *Pax6*-deficient RPE (E15.5). This analysis revealed a significant reduction in the expression of *D*-*Mitf*, which was over 3-fold lower in the mutants, and slight elevations in levels of *A*-*Mitf* and *H*-*Mitf* in the mutant RPE, compared to wild-type ([Figure 3E](#pgen-1004360-g003){ref-type="fig"}). Quantification of a downstream amplicon that is common to all *Mitf* isoforms revealed a significant 1.45-fold reduction in pan-*Mitf* transcripts, consistent with the microarray results. *In silico* analysis of the upstream regulatory region of *D-Mitf* revealed three putative binding sites for PAX6 PD and four for MITF ([Table S2](#pgen.1004360.s009){ref-type="supplementary-material"}); all are located within the 1200bp preceding the *D-Mitf* transcription start site (TSS) ([Figure 3F](#pgen-1004360-g003){ref-type="fig"}). An electrophoretic mobility shift assay (EMSA) revealed that PAX6 binds two of the three sites *in vitro* ([Figure 3G](#pgen-1004360-g003){ref-type="fig"}). This binding was specific, as it was competed by a cold probe ([Figure 3G](#pgen-1004360-g003){ref-type="fig"}). Luciferase reporter assay on regulatory sequences of *D*-*Mitf* (between −1,153 and +6 relative to the TSS) was performed using different combinations of *Pax6*, *Pax6ΔPD* and *Mitf* expression vectors ([Figure 3H](#pgen-1004360-g003){ref-type="fig"}). This analysis revealed synergistic transactivation of the *D-Mitf* promoter by PAX6 and MITF. The co-transfection of MITF with PAX6ΔPD failed to produce the same result.

![PAX6 is required for the expression of the *D*-*Mitf* isoform in the developing RPE.\
(A-D) Expression of MITF (red) and CHX10 (green) proteins detected by antibody labeling in the RPE of *Pax6^loxP/loxP^* control and *Pax6^loxP/loxP^;DctCre* mutant E12.5 and E15.5 eyes. Scale bar is 25 µm. (A\'-D\' insets) Higher magnifications of indicated regions and nuclear staining with DAPI. (E) Relative transcript levels of pan*-Mitf* and *M-*, *D-*, *H-* and *A-Mitf* isoforms in RPE fractions using QRT-PCR, \**p*\<0.05, \*\*\**p*\<0.0005, (n = 5). (F) A scheme of the *D-Mitf* upstream region showing the putative E-boxes (green rectangles) and PAX6 PD binding sites (light blue rectangles). Red arrows indicate the borders of deletion constructs used for luciferase assay. (G) EMSA examining the binding of PAX6 to the putative PAX6 PD binding sites upstream of the *D-Mitf* TSS (sites 1-3). The binding of PAX6 to probes 1 and 3 was inhibited using unlabeled probe containing the PAX6 consensus binding site (PAX6CON). (H) Activity of luciferase under the regulation of wild-type or truncated *D-Mitf* promoter co-transfected into HeLa cells along with different combinations of expression vectors and/or their backbones lacking the ORF (n = 3).](pgen.1004360.g003){#pgen-1004360-g003}

In order to identify the regulatory sequence required for PAX6 and MITF transcriptional activity, a series of *D-Mitf* truncated promoters was analyzed ([Figure 3H](#pgen-1004360-g003){ref-type="fig"}). The critical regulatory sequence for PAX6 and MITF transactivation is located between −310 and −180 relative to the TSS. This region contains only a PAX6 binding site (site 3: −212 and −194 relative to the TSS) but no known MITF binding site. Taken together, these results suggest that the transactivation of *D-Mitf* promoter by PAX6 and MITF depends on PAX6 PD and requires the PD binding site. These results also indicate that a self-sustaining PAX6-dependent feedback loop controls *Mitf* expression.

*D-Mitf* is dispensable for melanogenesis in the RPE {#s2d}
----------------------------------------------------

The abrogated melanogensis in the *Pax6*-deficient RPE and the corresponding reduction in the *D*-*Mitf* isoform suggested that the pigment depletion in the *Pax6*-deficient RPE could be mediated by *D-Mitf*. Recently mice with specific deletion of *D*-*Mitf* were generated by ablation of 0.2 kb downstream to exon *D*, exon *D* and the 5.6 kb preceding sequence (*Mitf^ΔD^*, [Figure S4C](#pgen.1004360.s004){ref-type="supplementary-material"}). In these mice, a slight reduction in pigmentation was observed at E11; however, at later stages the pigmentation was comparable to normal, in contrast to the depigmentation observed in the *Pax6^loxP/loxP^;DctCre* mutant eyes [@pgen.1004360-Bharti3] ([Figure 4A-C](#pgen-1004360-g004){ref-type="fig"}). Molecular analysis of *Mitf^ΔD/ΔD^* by IIF and QRT-PCR revealed that pan-*Mitf* level was similar to that in wild-type mice ([Figure 4D,E](#pgen-1004360-g004){ref-type="fig"}). Yet, the expression levels of *Mitf* variants in the *Mitf^ΔD/ΔD^* RPE were similar to the pattern observed in the *Pax6^loxP/loxP^;DctCre* mutants: *D*-*Mitf* transcript level was completely abolished while *A*-*Mitf* and *H*-*Mitf* expression levels were elevated ([Figure 4E](#pgen-1004360-g004){ref-type="fig"}). In addition, transcript quantification of the six melanogenic genes examined in the *Pax6*-deficient mutants revealed minor reductions in the levels of *Tyrp1*, *Si* and *Myo7a*, but only the reductions of the latter two were significant ([Figure 4F](#pgen-1004360-g004){ref-type="fig"}). The normal phenotype of *Mitf^ΔD/ΔD^* mice is probably due to redundant activity of the *Mitf* isoforms expressed in the RPE. Together, the above results reveal that while PAX6 is required for normal levels of expression of *D-Mitf*, the reduced levels of *D*-*Mitf* following *Pax6* loss cannot account for the observed arrest in melanogenesis in the *Pax6^loxP/loxP^;DctCre* mutants. Moreover, the dramatic loss of pigmentation, while levels of *Mitf* are partly maintained, indicates that PAX6 has other functions in melanogenesis of the RPE in addition to the regulation of *Mitf* levels.

![*D-Mitf* is dispensable for melanogenesis in the RPE.\
(A-C) Whole eye images of (A) *Pax6^loxP/loxP^*, (B) *Mitf^ΔD/ΔD^* and (C) *Pax6^loxP/loxP^;DctCre* mice. (D) A distal OC view of paraffin section of a *Mitf^ΔD/ΔD^* eye labeled with antibody against MITF. Arrows point at the RPE. (E) Relative transcript levels of pan*-Mitf* and *M-*, *D-*, *A-* and *H-Mitf* isoforms in RPE fractions determined using QRT-PCR. (F) Relative transcript levels of *Tyr*, *Tyrp1*, *Si*, *Mlana*, *Dct* and *Myo7a* in RPE fractions determined using QRT-PCR. \**p*\<0.05, \*\**p*\<0.005, (n = 5).](pgen.1004360.g004){#pgen-1004360-g004}

PAX6 enhances the transcriptional activity of MITF on downstream melanogenic factors {#s2e}
------------------------------------------------------------------------------------

The findings above reveal that PAX6 plays a pivotal role in the pigmentation program that goes beyond regulation of *D-Mitf* expression. This is reminiscent of the activity of the *Pax3* gene in melanocyte precursors, where it regulates the onset of *Mitf* expression as well as the expression of *Mitf* target genes like *Tyrp1* [@pgen.1004360-Galibert1]. In order to examine the ability of PAX6 to trans-activate known targets of MITF we performed luciferase reporter assays using the regulatory regions of three pigmentation genes: *mTyrp1, hTyr* and *mMlana* (see [Tables S3](#pgen.1004360.s010){ref-type="supplementary-material"}-[S5](#pgen.1004360.s012){ref-type="supplementary-material"} for details on MITF and PAX6 putative binding sites). We also examined the transcriptional activity of PAX6ΔPD, which was detected in *Pax6^loxP/loxP^;DctCre* mice ([Figure S1](#pgen.1004360.s001){ref-type="supplementary-material"} and [Figure S2](#pgen.1004360.s002){ref-type="supplementary-material"}), on these promoters. On the *mMlana* promoter there was additive cooperation between the two transcription factors (PAX6: 2.25 fold change, *p* = 0.02; MITF: 50.3 fold change, *p* = 0.004; MITF + PAX6: 149 fold change, *p*≤0.04; n = 3; [Figure S5](#pgen.1004360.s005){ref-type="supplementary-material"}). In contrast to PAX3, PAX6 by itself failed to activate the *mTyrp1* promoter either in pigment producing cell lines such as ARPE19 and UACC.62, or in HEK-293T, NIH-3T3 and HeLa cells ([Figure 5A](#pgen-1004360-g005){ref-type="fig"} and data not shown). However, in the presence of MITF, PAX6 cooperatively and synergistically trans-activated the m*Tyrp1* promoter (MITF: 5.6 fold change, *p* = 0.006; MITF + PAX6: 51.9 fold change, *p* = 0.002; n = 4; [Figure 5A](#pgen-1004360-g005){ref-type="fig"}). A similar synergistic transactivation pattern was observed using the *hTyr* promoter (MITF: 12.6 fold change, *p* = 0.001; MITF + PAX6: 71.3 fold change, *p* = 0.003; n = 3; [Figure 5B](#pgen-1004360-g005){ref-type="fig"}). Chromatin immunoprecipitation (ChIP) confirmed the association of PAX6 with the *hTyrp1* promoter region in RPE cells derived from human embryonic stem cells [@pgen.1004360-Idelson1]. We observed more than 4-fold enrichment of PAX6 in the *hTyrp1* proximal promoter compared to a region 2 kb downstream (data not shown and [Table S6](#pgen.1004360.s013){ref-type="supplementary-material"}).

![PAX6 trans-activates the promoters of *mTyrp1* and *hTyr* in the presence of MITF.\
(A,B) Activity of luciferase under the regulation of wild-type or mutated (A) *mTyrp1* or (B) *hTyr* promoters co-transfected into HeLa cells along with different combinations of expression vectors and/or their backbones lacking the ORF, as indicated (n = 3). The positions of binding sites for MITF (E/M-box, green rectangle) and potential binding sites for PAX6 (light blue rectangle) are indicated relative to the TSS of each promoter in schematics above each graph. (C) Activity of luciferase under the regulation of four consecutive M-boxes and a basic SV40 promoter co-transfected into HeLa cells along with different combinations of expression vectors and/or their backbones lacking the ORF, as indicated (n = 3). (D) Reciprocal co-immunoprecipitation assay of PAX6 and MITF using protein extracts of ARPE19 cells. Samples were precipitated using anti-PAX6 (lanes 4,7), anti-MITF (lane 3) or IgG (lanes 2,6). Anti-Pax6 (lanes 1-4) or anti-MITF (lanes 5-7) were used for Western blot.](pgen.1004360.g005){#pgen-1004360-g005}

We next examined the contributions of the putative binding sites of PAX6 and the binding sites of MITF (M- and E-box) to the transactivation of the promoters of *mTyrp1* and *hTyr* by PAX6 and MITF. Interestingly, deletion or point mutations in the MITF binding sites dramatically reduced the transactivation observed when MITF and PAX6 were co-expressed. While the wild-type *mTyrp1* promoter was trans-activated 51.9 fold in the presence of both factors, compared to their absence, a promoter carrying a deletion or mutations in the M-box was trans-activated only 3.5 fold ([Figure 5A](#pgen-1004360-g005){ref-type="fig"}). Similarly, the wild-type *hTyr* promoter was trans-activated 71.3 fold by both PAX6 and MITF, whereas promoters carrying mutations in the M- and E-box sequences were trans-activated 43.3 fold and 13.3 fold, respectively ([Figure 5B](#pgen-1004360-g005){ref-type="fig"}). In contrast, deletion of the putative binding site for PAX6 in *mTyrp1* promoter did not significantly alter the transactivation by MITF and PAX6 ([Figure 5A](#pgen-1004360-g005){ref-type="fig"}). To examine whether the M-box is sufficient to enhance MITF activity by PAX6, we performed a luciferase reporter assay with PAX6, MITF or both using a reporter with four consecutive M-box elements. As shown in [Figure 5C](#pgen-1004360-g005){ref-type="fig"}, PAX6 alone did not activate the promoter, MITF alone enhanced the activity by 6.6 fold, and PAX6 and MITF together enhanced the reporter activity by 11.9 fold (*p* = 0.046, n = 3). These findings suggest that in tissue culture, the MITF binding sites are essential and sufficient for the transactivation of *mTyrp1*and *hTyr* promoters by PAX6 and MITF.

The reporter assays revealed that PAX6 transactivation effects are largely dependent on MITF expression and on its binding sites. This mode of action suggests a physical interaction between PAX6 and MITF. We therefore conducted co-immunoprecipitation assays (co-IP) to evaluate this possibility. First, a reciprocal co-IP experiment was performed in ARPE19 cells that endogenously express both *Pax6* and *Mitf* [@pgen.1004360-Vugler1]. MITF antibodies co-precipitated PAX6, and immunoprecipitation with PAX6 antibodies resulted in precipitation of MITF ([Figure 5D](#pgen-1004360-g005){ref-type="fig"}). The enrichment of MITF in the PAX6 immunoprecipitate was very significant as MITF expression was almost below detection in the input sample ([Figure 5D, right panel](#pgen-1004360-g005){ref-type="fig"}, lane 5). These results support an association of MITF and PAX6 in ARPE19 cells.

To determine whether the PAX6ΔPD variant is capable of physical association with MITF, HeLa cells were transfected with 3xFLAG-PAX6, 3xFLAG-PAX6ΔPD, 3xFLAG-MITF or a combination of 3xFLAG-MITF with each PAX6 protein variant ([Figure S6A](#pgen.1004360.s006){ref-type="supplementary-material"}). Cells were harvested and protein extracts were precipitated using MITF antibodies. Both PAX6 and PAX6ΔPD proteins were enriched in the immunoprecipitates when co-transfected with MITF ([Figure S6A](#pgen.1004360.s006){ref-type="supplementary-material"}, right panel, lanes 9 and 10). These results suggest that the PAX6ΔPD variant is capable of associating with MITF as previously suggested [@pgen.1004360-Planque1]. We next conducted luciferase reporter assays using MITF and PAX6ΔPD. PAX6ΔPD had no transactivation effects on the transcriptional activity of MITF ([Figure 5A,B](#pgen-1004360-g005){ref-type="fig"}) and did not show a dominant negative effect on the transactivation of the *mTyrp1* promoter by MITF and PAX6 ([Figure S6B](#pgen.1004360.s006){ref-type="supplementary-material"}). These results indicate that although the PAX6ΔPD variant is capable of association with MITF, the PD domain is necessary for the PAX6-MITF-mediated transcriptional activation of melanogenic genes.

Discussion {#s3}
==========

This study unravels the molecular mechanism through which a single transcription factor, which is expressed in multiple ocular and non-ocular cell types, controls a highly specialized differentiation program of the neuroepithelium-derived pigmented cells of the eye. We show that PAX6 regulates a gene regulatory network central to RPE differentiation. This activity is mediated by a coherent feed-forward loop, by which PAX6 controls the expression of *Mitf* and jointly with MITF triggers the expression of multiple downstream target genes that are required for the execution of distinct differentiation program of pigment formation ([Figure 6](#pgen-1004360-g006){ref-type="fig"}). In this mode of action, MITF levels could serve as a sign-sensitive delay for the melanogenesis process in the RPE as transactivation of pigmentation genes by PAX6 depends on *Mitf* transactivation by PAX6. This type of kinetic mechanism filters out fluctuations in input stimuli since it requires persistent co-expression of both transcription factors. Our data provide an explanation of how PAX6, which is expressed in most ocular lineages, can promote the highly specialized and distinct differentiation program of the RPE.

![Model of PAX6 control of melanogenesis in the RPE through a positive feed forward loop with MITF.\
PAX6 positively regulates the expression of the *D*-*Mitf* isoform. There is a compensation mechanism that maintains pan-*Mitf* levels in the RPE. PAX6 cooperates with MITF to trans-activate several pigmentation genes.](pgen.1004360.g006){#pgen-1004360-g006}

A role for *Pax6* during specification of the OV to the PE lineage was deduced from the analyses of *Pax6* mutants that also carry mutations in the transcription factors *Pax2* or *D-Mitf*. The PE of the transgenic *Pax2^−/−^;Pax6^+/−^* and *Mitf^ΔD/ΔD^;Pax6^+/−^* mice develops into a second neuroretina [@pgen.1004360-Baumer1], [@pgen.1004360-Bharti3]. In contrast, RPE cells that lost the expression of *Pax6* after specification maintained their morphology of a single layer of polygonal epithelium ([Figure 1](#pgen-1004360-g001){ref-type="fig"}). Accordingly, we did not detect changes in the expression of several epithelial markers ([Figure 1O](#pgen-1004360-g001){ref-type="fig"}) or elevated expression of the neuronal gene CHX10 ([Figure 3A-D](#pgen-1004360-g003){ref-type="fig"}) in the *Pax6*-mutant RPE. Although the mutant RPE transcriptome data did not reveal overt elevations in neuronal genes, we did detect alterations in the expression levels of MITF-regulators, both key RPE-specification factors such as *Wnt2b* ([@pgen.1004360-Fuhrmann1]; −1.67, *p* = 0.00005) and *Gli2* ([@pgen.1004360-Perron1]; −1.1, *p* = 0.003) and of the retinal promoting gene *Msx2* ([@pgen.1004360-Holme1]; +1.8, *p* = 0.016). These alterations in gene expression suggest partial changes in the differentiation program of the *Pax6*-deficient RPE and point to additional regulators of MITF that are controlled by PAX6. However, these changes were not sufficient to completely disrupt RPE differentiation, in contrast to the complete disruption observed following inhibition of the Wnt/β-catenin pathway in specified RPE [@pgen.1004360-Fujimura1]. A previous study showed that PAX6 together with PAX2 is required for expression of MITF during the specification stage, and that the former two proteins regulate the expression of the *A-Mitf* isoform *in vitro* [@pgen.1004360-Baumer1]. In our analysis, the loss of *Pax6* during RPE differentiation resulted in up-regulation of *A-Mitf*. These findings suggest stage-dependent roles for PAX6 during various stages of RPE development, from pattering to differentiation.

We show that *Pax6* is essential for the proper expression of *Mitf* and its melanogenic target genes. This activity requires both PAX6 and MITF to act synergistically, as shown by luciferase reporter assays on the promoters of *mD-Mitf*, *mTyrp1* and *hTyr* ([Figure 3H](#pgen-1004360-g003){ref-type="fig"} and [Figure 5A,B](#pgen-1004360-g005){ref-type="fig"}). Although PAX6 binding sites were identified in each of these three promoters ([Tables S2](#pgen.1004360.s009){ref-type="supplementary-material"}-[S4](#pgen.1004360.s011){ref-type="supplementary-material"}), the deletion of the PAX6 binding site in the *Tyrp1* promoter did not reduce the transcriptional activity of PAX6 and MITF, while mutations in MITF binding sites in either *mTyrp1* or *hTyr* promoters hampered their activity ([Figure 5A,B](#pgen-1004360-g005){ref-type="fig"}). In contrast, the PAX6 binding site in the *D-Mitf* promoter (site 3, [Figure 3F,G](#pgen-1004360-g003){ref-type="fig"}), but not the putative MITF binding sites, was essential for PAX6 and MITF transcriptional activity ([Figure 3H](#pgen-1004360-g003){ref-type="fig"}). Together with the observation that PAX6 and MITF are capable of physical association ([Figure 5D](#pgen-1004360-g005){ref-type="fig"}), these results suggest that the PAX6-MITF complex may trans-activate promoters through either PAX6 or MITF binding sites. This mode of action of PAX6 may account for the broad spectrum of PAX6 transcriptional targets. ChIP-Seq studies on embryonic RPE or hES-RPE cells are underway to determine the promoter occupancy of PAX6 and MITF on RPE genes.

The *Mitf* gene encodes at least 10 isoforms with alternative promoter or exon usage. The three RPE-specific isoforms (*D-*, *A-* and *H*-*Mitf*; [@pgen.1004360-Bharti2], [@pgen.1004360-Li1]) differ only in the N-terminal sequences [@pgen.1004360-Takeda1]. The fact that all *Mitf* isoforms have different promoter sequences and predicted transcription factor binding sites suggests different regulation mechanisms [@pgen.1004360-Hallsson1]. Our data show that PAX6 is specifically required for the normal expression of *D-Mitf*. In both mouse mutant lines -- *Pax6^loxP/loxP^;DctCre* and *Mitf ^ΔD/ΔD^* --we observed an up-regulation of *A*-*Mitf* and *H*-*Mitf* isoforms ([Figure 3E](#pgen-1004360-g003){ref-type="fig"} and [Figure 4E](#pgen-1004360-g004){ref-type="fig"}). However, while in the RPE of *Mitf^ΔD/ΔD^* mice the total transcript level of *Mitf* was similar to that in the wild-type RPE, in the RPE of *Pax6^loxP/loxP^;DctCre* the level of pan-*Mitf* was 1.45-fold lower than the wild-type RPE. We therefore suggest that there is a feedback mechanism that balances the total level of MITF protein and that this mechanism requires full-length PAX6.

The observation that *A*- and *H*-*Mitf* are capable of compensating for the absence of *D*-*Mitf* activity in the *Mitf^ΔD/ΔD^* transgenic mice, but not in the *Pax6^loxP/loxP^;DctCre* mutants, suggests that reduction in pigmentation in the RPE of *Pax6^loxP/loxP^;DctCre* transgenic mice might be caused by down-regulation of a MITF co-factor, either PAX6 itself or another protein. Other than MITF, the only transcription factor that has been demonstrated to have a role in regulation of RPE melanogenesis is OTX2. OTX2 plays an important role in RPE development [@pgen.1004360-Bovolenta1], [@pgen.1004360-MartinezMorales1] by trans-activating the melanogenic enzymes-encoding genes *Tyr*, *Tyrp1* and *Dct* [@pgen.1004360-MartinezMorales2]--[@pgen.1004360-Reinisalo1]. Since we did not detect a significant change in the expression pattern of *Otx2* in the RPE of *Pax6^loxP/loxP^;DctCre* transgenic mice ([Figure S3](#pgen.1004360.s003){ref-type="supplementary-material"}), it is unlikely that changes in its expression mediate the reduction in the expression of the melanogenic genes and pigmentation observed following *Pax6* loss.

Another candidate that might be responsible for the reduced pigmentation in the *Pax6^loxP/loxP^;DctCre* is the bHLH leucine-zipper transcription factor TFEC. The amino acid sequences of TFEC and MITF bHLH leucine-zipper show high similarity [@pgen.1004360-Hallsson2] and these two proteins bind to an E-box as heterodimer complex [@pgen.1004360-Hemesath1]. Bharti et al. (2012) showed that PAX6 trans-activates the expression of *Tfec* and that *Tfec* can rescue eye defects in mice with a mutation in the *Mitf* gene [@pgen.1004360-Bharti3]. The transcript level of *Tfec* was indeed reduced in *Pax6^loxP/loxP^;DctCre* mutants ([Figure S7A](#pgen.1004360.s007){ref-type="supplementary-material"}: −1.23 fold change, *p* = 0.075, n = 6), and this minor down-regulation may have also contributed to the overall reduction in pigmentation, as TFEC is capable of trans-activating *mTyrp1* and *hTyr* promoters alone and synergistically with PAX6 ([Figure S7B](#pgen.1004360.s007){ref-type="supplementary-material"} and data not shown). Thus, in addition to its known role during PE specification, TFEC may also have a role in RPE differentiation where it acts like an additional isoform of MITF [@pgen.1004360-Hemesath1].

Association between PAX6 and MITF was previously shown *in vitro* by Planque et al. (2001). However, in that study transfection of the two proteins caused a reduction in MITF transactivation of *Tyr* promoter [@pgen.1004360-Planque1]. The discrepancy with our results could be explained by the different ratio of *Pax6*/*Mitf* levels used in the reporter assays, as Planque et al. used a ratio of 20∶1, whereas in our study the ratio was 1∶1. The importance of the ratio between PAX6 and MITF has also been demonstrated *in vivo*. The transcript levels of *Tyr* and *Tyrp1* were lower in mice that over-express *Pax6* (i.e. *Pax6^Yac/Yac^* mice) on the background of a *Mitf^ΔD/ΔD^* transgenic mice compared to either *Pax6^Yac/Yac^* or *Mitf^ΔD/ΔD^* alone [@pgen.1004360-Bharti3]. In these experiments, RPE pigmentation levels were consistent with the altered expression levels of *Tyr* and *Tyrp1* ([@pgen.1004360-Bharti3] and Bharti, unpublished results). Interestingly, while during embryonic development PAX6 is eliminated from the RPE in a proximal to distal gradient, MITF and its downstream pigmentation genes are expressed along the entire length of the RPE. Thus, we infer that PAX6 is involved in the initiation of the pigmentation program but not in its maintenance.

The somatic mutation induced by the *DctCre* transgene deleted exons 4−6, which encode the initiation codon and the PD of PAX6. Interestingly, while the PD was eliminated from the *Pax6^loxP/loxP^;DctCre* embryos, a truncated transcript of *Pax6* that gave rise to a *Pax6ΔPD* variant was identified. The PAX6*Δ*PD variant was not previously noted in somatic mutations of the *Pax6^loxP^* allele [@pgen.1004360-AsheryPadan1], , probably because in some tissues, such as the lens placode and the peripheral optic cup, but not in the RPE, the expression of *Pax6* depends on full-length PAX6 protein [@pgen.1004360-Grindley1], which is absent due to the Cre-mediated deletion. In addition, it is possible that RPE-specific post-transcriptional mechanisms that alter splicing and RNA stability lead to more prominent accumulation of the PAX6ΔPD in the RPE.

While the physiological activity of PAX6ΔPD in the eye is still unknown, its over-expression results in microphthalmia due to aberrant lens and corneal development [@pgen.1004360-Kim1], [@pgen.1004360-Kim2]. Thus, although we did not detect over-expression of the homeodomain of *Pax6*, we should consider the possible contribution of the over-expression of the PAX6*Δ*PD isoform and the disruption of the PAX6/PAX6*Δ*PD ratio to the pigment phenotype of the *Pax6^loxP/loxP^;Dct-Cre* RPE. There are several lines of evidence that rule out a major effect of the PAX6ΔPD isoform in the *Pax6^loxP/loxP^;Dct-Cre* mutants: First, we detected a *Pax6ΔPD* transcript in the control RPE, which was initiated from the P4 promoter ([Figure S2A](#pgen.1004360.s002){ref-type="supplementary-material"},C,E). Thus, the *Pax6ΔPD* transcript is expressed during normal differentiation and onset of pigmentation in the RPE. Second, *Pax6ΔPD* is expressed in the progenitors of the CB and is maintained there in the adult, both in the pigmented and non-pigmented epithelium [@pgen.1004360-Kim2]. Yet, mice carrying 10 copies of the *Pax6* locus and over-expressing *Pax6ΔPD* do not display any alteration in the pigmentation of the CB [@pgen.1004360-Kim2]. Therefore the PAX6ΔPD isoform is unlikely to interfere with the pigmentation program. Third, we did not detect reduced pigmentation in the RPE of *Pax6^loxP/+^;DctCre* heterozygous mice, thus further arguing against a dominant-negative effect of this truncated product ([@pgen.1004360-Davis1] and data not shown). Finally, even though the PAX6ΔPD isoform was able to associate with MITF in a co-IP assay ([Figure S6A](#pgen.1004360.s006){ref-type="supplementary-material"}), it had no repressive or inductive effects on the promoters of *mTyrp1* and *hTyr* either alone or when co-expressed with MITF or together with MITF and PAX6 ([Figure 5A,B](#pgen-1004360-g005){ref-type="fig"} and [Figure S6B](#pgen.1004360.s006){ref-type="supplementary-material"}).

Although there is little evidence for independent eye invention events during metazoan species evolution [@pgen.1004360-Kozmik1], there is strong argument in favor of a common molecular network controlling the development of the metazoan eye, in which *Pax* genes were redundantly employed and were later on variably adapted for eye development in different animal taxa [@pgen.1004360-Kozmik1], . According to this hypothesis an ancestor of a *Pax6* gene was at the node of a gene regulatory network that controlled the morphogenesis of a primitive eye composed of a photoreceptor cell that contained pigment granules, as in *Palaemonetes pugio* [@pgen.1004360-Doughtie1]. The evolutionarily earliest gene regulatory networks were likely to be hierarchically shallow and, as animal body parts gradually elaborated and gained more complex regional subdivision of the developing embryo, the underlying regulatory networks became hierarchically deeper and were terminally fixed into kernel genes, in which any minor change would lead to extremely harmful consequences [@pgen.1004360-Davidson1], [@pgen.1004360-Davidson2]. In such a scenario, the development of the vertebrate eye into a complex structure that includes PE and multilayered neuroretina would require different cell specific transcription factors that in combination with PAX6 generate different *cis*-regulatory input functions that result in execution of distinct and highly specified differentiation programs. In this model, PAX6 acts as an accelerator directed by its tissue-specific partner to a specific transcriptional program.

Material and Methods {#s4}
====================

Mouse lines {#s4a}
-----------

The mouse lines employed in this study, *Mitf^ΔD^* [@pgen.1004360-Bharti3], *Pax6^loxP^* [@pgen.1004360-AsheryPadan1] and *DctCre* [@pgen.1004360-Davis1] have been previously described. The latter two were used to establish *Pax6^loxP/loxP^;DctCre* somatic mutants. *Pax6^loxP/loxP^* littermates were used as controls. The genetic background of all mice used in this study was C57BL/6J, except for *in situ* staining, for which mice of the outbred ICR genetic background were used. All animal work was conducted according to national and international guidelines and approved by the Tel Aviv University review board.

Statistical analysis {#s4b}
--------------------

All data were examined using two-tailed Student\'s t-test.

Immunofluorescence, ISH and flat-mount {#s4c}
--------------------------------------

Immunofluorescence analysis was performed on 10 µm paraffin sections as previously described [@pgen.1004360-AsheryPadan1], using the following primary antibodies: rabbit anti-PAX6 (1∶400, Covance, prb-278b), mouse anti-PAX6 (1∶25, Santa Cruz, sc-32766), rabbit anti-SOX9 (1∶200, Chemicon, ab5535), sheep anti-CHX10 (1∶1000, Exalpha, X1180P), rabbit anti-OTX2 (1∶50, Millipore, AB9566), rabbit anti-MITF [@pgen.1004360-Bharti2], rabbit anti-TYR (1∶1,000, a gift from the Vincent Hearing lab, NCI), rabbit anti-TYRP1 (1∶1,000, a gift from the Vincent Hearing lab, NCI). Secondary antibodies were donkey anti-rabbit conjugated to alexa594 (1∶1000, Invitrogen, A21207) and alexa488 donkey anti mouse/sheep (1∶1000, Invitrogen, A21202/A11015).

*In situ* hybridization (ISH) was performed on 14 µm cryo-sections using DIG-labeled RNA probes as previously described [@pgen.1004360-Yaron1]. The *Pax6* intron 7 probe was generated from a 849bp PCR fragment (forward, 5′-TTTGGAGCCCTCCATCTTTCTC-3′; reverse, 5′- TGCACACTTTCGGGCAAGG-3′). Plasmid for antisense transcription of *silver* was kindly provided by the laboratory of Dr. William Pavan (NIH) [@pgen.1004360-Baxter1].

Flat-mount samples were prepared as follows: Eyes at E19.5 were enucleated and immediately fixed in 4% paraformaldehyde for 30 minutes. The RPE was carefully dissected from the rest of eye structures, sliced radially to four pieces and flattened on membrane filters (Schleicher& Schull, 0.45 µm D-37582). Samples were blocked and stained with phalloidin (1∶100, Invitrogen, A12379). Thereafter, RPE was flattened on its basal side on a slide and sealed for observation.

Transmission electron microscopy {#s4d}
--------------------------------

The heads of E15.5 embryos and perforated eyes of P1 neonatal mice were fixed in 0.1 M cacodylate-buffered fixative containing 2.5% paraformaldehyde and 2% glutaraldehyde and further processed as described previously [@pgen.1004360-Baba1]. Ultrathin sections were cut with a Leica Ultramicrotome UCT (Leica Microsystems), stained with uranyl acetate and lead citrate and analyzed with a H7600 transmission electron microscope (Hitachi).

RNA isolation and microarray analysis {#s4e}
-------------------------------------

Exact timed matings were performed by overnight cohabitation of an inbred *Pax6^loxP/loxP^;DctCre* male with *Pax6^loxP/loxP^* females. Pregnant females were harvested on day E15.5 and the RPE of the embryos was dissected as previously described [@pgen.1004360-Bharti2]. RPEs were pooled into two separate tubes according to their pigmentation intensity, and tubes were stored at −80°C. Tail cuts of the embryos were collected for genotype verification. Each tube was considered as one biological repeat. RNA was extracted using the QIAshredder and the RNeasy kits (QIAGEN). RNA isolated from three control and three mutant samples was processed for microarray analysis using the Affymetrix GeneChip 1.0ST as described previously [@pgen.1004360-Shaham3]. Differentially expressed genes with p-values lower than 0.05 and with a fold-change cutoff of 1.5 are listed in [Table S1](#pgen.1004360.s008){ref-type="supplementary-material"}. The expression data were submitted to the NCBI Gene Expression Omnibus (<http://www.ncbi.nlm.nih.gov/geo>) under series accession no. GSE56548.

Reverse transcription and quantitative real-time and end-point PCR {#s4f}
------------------------------------------------------------------

Reverse transcription of 1 µg of RNA from each sample was performed using the SuperScript III First Strand kit (Invitrogen). cDNA was amplified using the Power SYBR Green Mix (Applied Biosystems) in a 384-well optical reaction plate using ABI Prism 7000 Sequence Detection System (Applied Biosystems). All primer pairs were first tested for specificity and amplicon size using end-point PCR. Formation of a dimer structure was refuted by analyzing the dissociation curve at the end of each amplification reaction. Results were calibrated in relation to an average of two house-keeping genes, *Ppia* and *Tbp*, after verifying that their levels were consistent in normal and mutant RPE. Raw data was processed using the comparative C~t~ method by the formula 2^−ΔΔCT^. Each amplification reaction was performed in triplicate using 20 ng of cDNA for each sample. Primers used to amplify and sequence the two *Pax6ΔPD* transcript variants are listed in [Table S6](#pgen.1004360.s013){ref-type="supplementary-material"}.

Luciferase reporter assay {#s4g}
-------------------------

Reporter assays were performed in HeLa cells using the Dual-Luciferase Reporter Assay System (Promega). Cells were seeded in a 24-well plate and 24 hours later were transfected using jetPEI DNA transfection reagent (Polyplus-transfection). Each well was co-transfected with three types of vectors in a total amount of 1210 ng of DNA: 1) 400 ng of a luciferase reporter vector (pGL3 basic) under the regulation of the examined promoter; 2) A total of 800 ng of expression vector (p3XFlag-CMV-10), either carrying no insert or containing an insert encoding the ORF of *Pax6*, *Pax6ΔPD* or *A-Mitf*, 400 ng of each; 3) 10 ng normalizing vector (pRL-TK). Cells were harvested 48 hours after transfection and luminescence was evaluated. Each treatment was carried out in duplicate, and each assay was repeated at least three times.

Site-directed mutagenesis {#s4h}
-------------------------

End-point PCR of 17 cycles was performed using oligonucleotides containing the desired mutated sites ([Table S6](#pgen.1004360.s013){ref-type="supplementary-material"}, mutated nucleotides are in lower case) and the wild-type promoter reporter plasmid (pGL3 basic) as template. The PCR products were treated with 12U *Dpn*I restriction enzyme (Fermentas) for 1 hour at 37°C, and 5 µl of the DNA was transformed into *E. coli XL-1Blue* strain, followed by colony-picking mini-prep and midi-prep plasmid purification (Qiagen). All plasmids were verified by sequencing.

Immunoprecipitation and immunoblotting {#s4i}
--------------------------------------

Transfection into HeLa cells was performed as described in the reporter assay section. Cells were seeded in 90-mm dishes and transfected with total of 10 µg of DNA. Cells were washed with phosphate buffered saline (PBS), scraped in 1 ml lysis buffer (10 mM HEPES pH 8.0, 100 mM NaCl, 1 mM MgCl~2~, 0.5% NP-40) containing protease inhibitor (Roche, complete Mini EDTA-free) and incubated on ice for 30 minutes. Extracts were clarified by centrifugation at 10,000 g for 15 minutes at 4°C. To avoid nonspecific binding of proteins to the beads, extracts were subjected to pre-clearing using 15 µl of protein A agarose beads (Millipore, 16-157) for 2 hours at 4°C, followed by centrifugation at 10,000 g for 1 minute at 4°C. Input samples (50 µl of the supernatant) were kept at −20°C for input analysis and the cleared extracts were incubated with 5 µl of rabbit anti-MITF (kindly provided by David E. Fisher, MGH [@pgen.1004360-Levy2]) with rotation overnight at 4°C. The resulting immuno-complexes were incubated with 30 µl of protein A beads for 2 hours at 4°C. The beads were then washed four times with RIPA buffer (50 mM Tris-HCl pH 8.0, 150 mM NaCl, 1% NP-40, 0.5% Na-deoxycholate, 0.1% SDS) and the complexes were eluted in SDS sample buffer by boiling for 5 minutes. Samples were subjected to SDS--polyacrylamide gel electrophoresis. Separated proteins were transferred to nitrocellulose membrane and reacted with mouse anti-FLAG antibody (1∶10,000, Sigma F3165) followed by anti-mouse horseradish peroxidase-conjugated secondary antibody. The reaction was examined by enhanced chemiluminescence detection kit (Biological Industries).

Co-immunoprecipitation from ARPE19 cells was performed essentially as described above, except cells were scraped in RIPA buffer containing protease inhibitor (Roche, complete Mini EDTA-free). Antibodies used for IP were either rabbit anti-PAX6 (Millipore, AB2237) or rabbit anti-MIT (kindly provided by David E. Fisher, MGH). Mouse anti-PAX6 (Santa Cruz, sc-3276) and mouse anti-MITF (kindly provided by David E. Fisher, MGH [@pgen.1004360-Levy2]) antibodies were used for immunoblot.

ChIP was performed as previously described [@pgen.1004360-Sailaja1], [@pgen.1004360-Sailaja2]. Briefly, hES-RPE cells were grown as described [@pgen.1004360-Idelson1]. Fixed chromatin was extracted from 2×10^7^ cells and immunoprecipitated using rabbit anti-PAX6 (Millipore, AB2237) or non-immune rabbit IgG (Rockland) as a negative control. The primers used for ChIP analysis are listed in [Table S6](#pgen.1004360.s013){ref-type="supplementary-material"}.

Electrophoretic mobility shift assay (EMSA) {#s4j}
-------------------------------------------

HEK-293T cells were transfected with p3XFlag-CMV-10 encoding the ORF of full-length *Pax6*. Nuclear extracts were obtained as previously described [@pgen.1004360-HayKoren1]. Nuclear extract (1 ml) or 1∶10 diluted nuclear extract was incubated for 10 minutes on ice in 8.5 mM HEPES pH 7.9, 30 mM KCl, 1.5 mM MgCl~2~, 0.4 mM DTT, 2 mg polydI/dC (Sigma). Binding with 1 ml double-stranded 59-c-ATP-labeled probe (30,000 cpm) was performed at room temperature for 20 minutes and 200 ng of ''cold'' PAX6 consensus site (PAX6CON) was used for competition [@pgen.1004360-Wolf1].

Supporting Information {#s5}
======================

###### 

A PAX6ΔPD protein is expressed in the RPE of *Pax6^loxP/loxP^;DctCre* mutant mice. Paraffin sections of (A-D) control, *Pax6^loxP/loxP^*, and (E-H) mutant, *Pax6^loxP/loxP^;DctCre*, eyes stained for the N-terminus (red, amino acids 1-206) and C-terminus (green, last 18 amino acids) of PAX6. (A\'-H\' insets) Higher magnifications of indicated regions and nuclear staining with DAPI. (E-H\') PAX6PD is not detected in the RPE of *Pax6^loxP/loxP^;DctCre* mutants at E12.5, E15.5 or E19.5 (red). Nevertheless, a PAX6ΔPD polypeptide is detected in the *Pax6^loxP/loxP^;DctCre* RPE (green). The spatiotemporal expression pattern of PAX6 isoforms is similar in wild-type and *Pax6^loxP/loxP^;DctCre* RPE: (A,E) at E12.5, PAX6 isoforms are expressed in the entire RPE; (B,F) at E15.5, PAX6 isoforms are highly expressed in the distal RPE; (D,H) and at E19.5 PAX6 isoforms are expressed only in the distal most cells of the RPE. (C\',D\',G\',H\' insets) The boundary region along the RPE, where the expression of PAX6 isoform is gradually reduced, is shown in higher magnifications. Scale bar is 50 µm.

(TIF)

###### 

Click here for additional data file.

###### 

***Pax6*** **gene structure and transcripts expressed in the RPE of** ***Pax6^loxP/loxP^;DctCre*** **mutant and control mice.** (A) A scheme of *Pax6ΔPD* transcript expressed under the regulation of the P4 promoter. Striped rectangle indicates the location of the ISH probe used to identify the expression pattern of the *Pax6ΔPD* transcribed from promoter P4. (B) A scheme of the abnormal *Pax6ΔPD* transcript that is expressed in the RPE of *Pax6^loxP/loxP^;DctCre* mice. Coding exons are marked with large rectangles and non-coding exons are marked with small rectangles. The PD and HD coding exons are marked in light blue and blue, respectively. Locations of primers that were used to sequence the two *Pax6ΔPD* variants are marked with red arrows. Locations of possible start codons for the *Pax6ΔPD* transcript variants are indicated by ATG codons. (C) PCR products generated using primers designed to ampliy a *Pax6* intron 7 to exon 9 fragment, suggestive of the product shown in panel A. (D) PCR products generated using primers designed to ampliy the a *Pax6* exon 3 to exon 8 fragment, suggestive of the product shown in panel B. (E) A view of the distal OC of cryo-section subjected to *in situ* hybridization with a probe corresponding to *Pax6* intron 7. Scale bar is 50 µm. (F) Transcript levels of *Pax6* exons 7-8 in the RPE of control *Pax6^loxP/loxP^* and mutant *Pax6^loxP/loxP^;DctCre* mice at E15.5.

(TIF)

###### 

Click here for additional data file.

###### 

Expression of the RPE transcription factors *Otx2* and *Sox9* was similar in wild-type and *Pax6^loxP/loxP^;DctCre* mice. (A) Relative transcript levels of *Otx2* and *Sox9* in RPE fractions from wild-type and mutant mice determined using QRT-PCR (n = 5). (B-E) Distal OC view of paraffin sections labeled with antibodies against (B,D) OTX2 and (C,E) SOX9. Scale bar is 25 µm. Only few cells in the distal most region of the RPE of *Pax6^loxP/loxP^;DctCre* do not express OTX2 (B\',D\' insets). The expression of SOX9 in a proximal to distal gradient is maintained in the RPE of *Pax6^loxP/loxP^;DctCre* mutants. (C\',E\' insets) The boundary region along the RPE, where the expression of SOX9 gradually increases.

(TIF)

###### 

Click here for additional data file.

###### 

Schemes of the mouse *Mitf* gene locus, the deleted DNA segment in the *Mitf^ΔD/ΔD^* transgenic mice and the different MITF isoforms expressed in the RPE and choroid. (A) Scheme of *Mitf* gene structure presenting only the exons that constitute the four main isoforms expressed in the RPE (*A*-, *D*- and *H-Mitf*) and choroid (*M-Mitf*). The alternative transcription (TSS) and translation (ATG) start sites are indicated. White rectangles mark untranslated regions and colored rectangles mark coding sequences. A graphic scheme of all known *Mitf* isoforms and their unique alternative first exons is presented in Bharti et al. (2008) [@pgen.1004360-Bharti2]. (B) The four MITF protein isoforms relevant to this study. Each isoform consist of different amino termini region. (C) An enlargement of the rectangular inset in (A). In the *Mitf^ΔD^* transgenic allele, a 5.8 kb DNA fragment that includes exon *D* (25bp) and covers a region of ∼200bp downstream and ∼5.6 kb upstream to the *D-Mitf* TSS was replaced by a neomycin cassette [@pgen.1004360-Bharti3].

(TIF)

###### 

Click here for additional data file.

###### 

PAX6 trans-activates the promoters of *mMlana* in the presence of MITF. Activity of luciferase under the regulation of the *mMlana* promoter co-transfected into HeLa cells along with different combinations of expression vectors and/or their backbones lacking the ORF, as indicated (n = 3). The positions of binding sites for MITF (E-box, green rectangles) and potential binding sites for PAX6 (light blue rectangles) are indicated relative to the TSS.

(TIF)

###### 

Click here for additional data file.

###### 

The PAX6ΔPD variant is capable of association with MITF but probably does not take part in the MITF-mediated transcriptional activation of melanogenic genes. (A) co-IP of MITF and PAX6 or PAX6ΔPD. HeLa cells were transfected with vectors expressing 3xFlagPax6, 3xFlagMitf, 3xFlagPax6ΔPD or their combinations, as indicated. Cell lysates were prepared (input) and immunoprecipitated with anti-MITF antibodies. Samples were subjected to SDS-PAGE and analyzed by immunoblotting with anti-FLAG antibody (input: lanes 1-5; IP: lanes 6-10). Both full-length PAX6 and PAX6ΔPD were found to be in association with MITF (lanes 9-10). (B) Activity of luciferase under the regulation of wild-type m*Tyrp1* promoter co-transfected into HeLa cells along with different combinations and amounts of expression vectors and/or their backbones lacking the ORF, as indicated. PAX6ΔPD had no effect on PAX6-MITF mediated transactivation of the *mTyrp1* promoter.

(TIF)

###### 

Click here for additional data file.

###### 

The slight reduction in *Tfec* transcript level in the RPE of *Pax6^loxP/loxP^;DctCre* mice may contribute to the reduction in pigmentation. (A) Activity of luciferase under the regulation of wild-type m*Tyrp1* promoter (promoter scheme shown in [Figure 5A](#pgen-1004360-g005){ref-type="fig"}) co-transfected into HeLa cells along with different combinations of expression vectors and/or their backbones lacking the ORF, as indicated. (B) Relative transcript levels of *Tfec* in wild-type and *Pax6^loxP/loxP^;DctCre* RPE fractions using QRT-PCR (n = 6).

(TIF)

###### 

Click here for additional data file.

###### 

Genes differentially expressed in the *Pax6*-deficient RPE relative to wild-type RPE according to the microarray results.

(DOCX)

###### 

Click here for additional data file.

###### 

Putative MITF and PAX6 binding sites in *mD-Mitf* promoter (from +6 to −1153 relative to the TSS).

(DOCX)

###### 

Click here for additional data file.

###### 

Putative MITF and PAX6 binding sites in *mTyrp1* promoter (from +5 to −252 relative to the TSS).

(DOCX)

###### 

Click here for additional data file.

###### 

Putative MITF and PAX6 binding sites in *hTyr* promoter (from +80 to −115 relative to the TSS).

(DOCX)

###### 

Click here for additional data file.

###### 

Putative MITF and PAX6 binding sites in promoter of *mMlana* (from +6 to −1153 relative to the TSS).

(DOCX)

###### 

Click here for additional data file.

###### 

Primers used in this study.

(DOCX)
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Click here for additional data file.
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Supporting references.

(DOCX)
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Click here for additional data file.
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